Trends Pharmacol Sci 1993,14(2):61–8.PubMedCrossRef 201. Sattler FR, Castaneda-Sceppa C, Binder EF, Schroeder ET, Wang Y, Bhasin S, Kawakubo M, Stewart Y, Yarasheski KE, Ulloor J, Colletti P, Roubenoff R, Azen SP: Testosterone and growth hormone improve body composition and muscle performance in older men. J Clin Endocrinol Metab 2009,94(6):1991–2001.PubMedCrossRef 202. Storer TW, Woodhouse L, Magliano L,
Singh AB, Dzekov C, Dzekov J, Bhasin S: Changes in muscle mass, muscle strength, and power but not physical function are related to testosterone dose in healthy older men. J Am Geriatr Soc 2008,56(11):1991–9.PubMedCrossRef 203. Wagner JC: Enhancement of athletic performance with drugs. An overview. Sports Med 1991,12(4):250–65.PubMedCrossRef 204. Yarasheski KE: Growth hormone effects on metabolism, body composition, muscle mass, and strength. Exerc Sport Sci Rev 1994, 22:285–312.PubMedCrossRef
17-AAG purchase 205. Smart T: Other Selleckchem NU7441 therapies for Protein Tyrosine Kinase inhibitor wasting. GMHC Treat Issues 1995,9(5):7–8. 12 206. Casaburi R: Skeletal muscle dysfunction in chronic obstructive pulmonary disease. Med Sci Sports Exerc 2001,33(7 Suppl):S662–70.PubMed 207. Hayes VY, Urban RJ, Jiang J, Marcell TJ, Helgeson K, Mauras N: Recombinant human growth hormone and recombinant human insulin-like growth factor I diminish the catabolic effects of hypogonadism in man: metabolic and molecular effects. J Clin Endocrinol Metab 2001,86(5):2211–9.PubMedCrossRef SB-3CT 208. Newshan G, Leon W: The use of anabolic agents in HIV disease. Int J STD AIDS 2001,12(3):141–4.PubMedCrossRef 209. Tenover JS: Androgen replacement therapy to reverse and/or prevent age-associated sarcopenia in men. Baillieres Clin Endocrinol Metab 1998,12(3):419–25.PubMedCrossRef 210. Bross R, Casaburi R, Storer TW, Bhasin S: Androgen effects on body composition and muscle function: implications for the use of androgens as anabolic agents in sarcopenic states. Baillieres Clin Endocrinol Metab 1998,12(3):365–78.PubMedCrossRef 211. Casaburi R: Rationale
for anabolic therapy to facilitate rehabilitation in chronic obstructive pulmonary disease. Baillieres Clin Endocrinol Metab 1998,12(3):407–18.PubMedCrossRef 212. Johansen KL, Mulligan K, Schambelan M: Anabolic effects of nandrolone decanoate in patients receiving dialysis: a randomized controlled trial. Jama 1999,281(14):1275–81.PubMedCrossRef 213. Sattler FR, Jaque SV, Schroeder ET, Olson C, Dube MP, Martinez C, Briggs W, Horton R, Azen S: Effects of pharmacological doses of nandrolone decanoate and progressive resistance training in immunodeficient patients infected with human immunodeficiency virus. J Clin Endocrinol Metab 1999,84(4):1268–76.PubMedCrossRef 214. Beiner JM, Jokl P, Cholewicki J, Panjabi MM: The effect of anabolic steroids and corticosteroids on healing of muscle contusion injury. Am J Sports Med 1999,27(1):2–9.PubMed 215.